Lauren E Howard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8786967/publications.pdf

Version: 2024-02-01

377584 445137 82 1,456 21 33 citations h-index g-index papers 82 82 82 2895 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer. Molecular Therapy, 2022, 30, 485-500.	3.7	17
2	Context-Based Identification of Muscle Invasion Status in Patients With Bladder Cancer Using Natural Language Processing. JCO Clinical Cancer Informatics, 2022, 6, e2100097.	1.0	3
3	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 762-769.	2.0	13
4	Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 770-777.	2.0	5
5	Weight loss via a low-carbohydrate diet improved the intestinal permeability marker, zonulin, in prostate cancer patients. Annals of Medicine, 2022, 54, 1221-1225.	1.5	4
6	Partial Validation of the Sleep Health Construct in the Medical Outcomes Study Sleep Questionnaire. Journal of Clinical Psychology in Medical Settings, 2021, 28, 168-173.	0.8	0
7	Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH. Urology, 2021, 149, 181-186.	0.5	3
8	Safety of concomitant therapy with radiumâ€223 and abiraterone or enzalutamide in a realâ€world population. Prostate, 2021, 81, 390-397.	1.2	5
9	Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. JNCI Cancer Spectrum, 2021, 5, pkab023.	1.4	13
10	Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial. Journal of Urology, 2021, 205, 1733-1739.	0.2	5
11	Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer. Journal of Urology, 2021, 206, 1411-1419.	0.2	3
12	Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients. Journal of Urology, 2021, 206, 499-501.	0.2	1
13	Outcomes of adjunctive therapies post hedgehog inhibitors in the management of locally advanced basal cell carcinoma: A systematic review and pooled analysis. Dermatologic Therapy, 2021, 34, e15172.	0.8	3
14	Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (<scp>REDUCE)</scp> trial. BJU International, 2020, 125, 226-233.	1.3	5
15	Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer and Prostatic Diseases, 2020, 23, 419-428.	2.0	22
16	Low Carbohydrate Diets in Men with Prostate Cancer May Reduce Risk of Cardiovascular Disease. Current Developments in Nutrition, 2020, 4, nzaa044_031.	0.1	0
17	Obese men undergoing radical prostatectomy: Is robotic or retropubic better to limit positive surgical margins? Results from SEARCH. International Journal of Urology, 2020, 27, 851-857.	0.5	6
18	Race does not predict skeletalâ€related events and allâ€cause mortality in men with castrationâ€resistant prostate cancer. Cancer, 2020, 126, 3274-3280.	2.0	3

#	Article	lF	CITATIONS
19	A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). Clinical Cancer Research, 2020, 26, 3035-3043.	3.2	31
20	Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer. Anticancer Research, 2020, 40, 1459-1462.	0.5	11
21	Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. Journal of Urology, 2020, 203, 120-127.	0.2	3
22	Racial Discrepancies in Overall Survival among Men Treated with ²²³ Radium. Journal of Urology, 2020, 203, 331-337.	0.2	25
23	Reply by Authors. Journal of Urology, 2020, 203, 127-127.	0.2	0
24	Predictors of skeletalâ€related events and mortality in men with metastatic, castrationâ€resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer, 2019, 125, 4003-4010.	2.0	15
25	Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy. Cancer Epidemiology, 2019, 62, 101578.	0.8	14
26	Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?. Clinical Genitourinary Cancer, 2019, 17, e930-e938.	0.9	1
27	Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 633-635.	2.0	13
28	A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1)Ärandomized controlled trial. Prostate Cancer and Prostatic Diseases, 2019, 22, 428-437.	2.0	44
29	Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 289.e11-289.e17.	0.8	16
30	Interplay between exercise and BMI; results from an equal access, racially diverse biopsy study. Cancer Causes and Control, 2019, 30, 13-20.	0.8	2
31	Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer, 2019, 125, 3025-3032.	2.0	3
32	Poorly controlled diabetes increases the risk of metastases and castrationâ€resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer, 2019, 125, 2861-2867.	2.0	20
33	Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men. Cancer Letters, 2019, 449, 99-105.	3.2	6
34	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	2.0	66
35	Nocturia and associated mortality: observational data from the REDUCE trial. Prostate Cancer and Prostatic Diseases, 2019, 22, 77-83.	2.0	14
36	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 783-789.	1.1	1

3

#	Article	IF	CITATIONS
37	Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes and Control, 2018, 29, 581-588.	0.8	30
38	First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e17-239.e25.	0.8	12
39	Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. Journal of Urology, 2018, 199, 713-718.	0.2	7
40	Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE. Journal of Urology, 2018, 199, 536-542.	0.2	19
41	Impact of prior local therapy on overall survival in men with metastatic castrationâ€resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. International Journal of Urology, 2018, 25, 998-1004.	0.5	13
42	PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2018, 21, 238-244.	2.0	12
43	Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. Journal of Urology, 2018, 200, 758-766.	0.2	48
44	Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort. Cancer Prevention Research, 2018, 11, 621-628.	0.7	15
45	Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort. Urology, 2017, 105, 129-135.	0.5	16
46	Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE. Journal of Urology, 2017, 198, 650-656.	0.2	3
47	Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer Prevention Research, 2017, 10, 319-326.	0.7	23
48	Thresholds for <scp>PSA</scp> doubling time in men with nonâ€metastatic castrationâ€resistant prostate cancer. BJU International, 2017, 120, E80-E86.	1.3	46
49	Factors predicting skeletalâ€related events in patients with bone metastatic castrationâ€resistant prostate cancer. Cancer, 2017, 123, 1528-1535.	2.0	22
50	Association of Obesityâ€Related Hemodilution of Prostateâ€Specific Antigen, Dihydrotestosterone, and Testosterone. Prostate, 2017, 77, 466-470.	1.2	25
51	Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate, 2017, 77, 1592-1600.	1.2	8
52	Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology, 2017, 108, 129-134.	0.5	17
53	Predictors of operative time during radical retropubic prostatectomy and robotâ€assisted laparoscopic prostatectomy. International Journal of Urology, 2017, 24, 618-623.	0.5	16
54	Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer, 2017, 123, 4199-4206.	2.0	30

#	Article	IF	CITATIONS
55	Number of Unfavorable Intermediateâ€Risk Factors Predicts Pathologic Upstaging and Prostate Cancerâ€Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate, 2017, 77, 154-163.	1.2	22
56	In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. European Urology Focus, 2017, 3, 480-486.	1.6	11
57	Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clinical Genitourinary Cancer, 2017, 15, 60-66.e2.	0.9	79
58	UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression. BMC Cancer, 2017, 17, 463.	1.1	13
59	Racial differences in prostate inflammation: results from the REDUCE study. Oncotarget, 2017, 8, 71393-71399.	0.8	10
60	Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk. Oncotarget, 2017, 8, 94900-94909.	0.8	29
61	The association between sexual function and prostate cancer risk in US veterans. Asian Journal of Andrology, 2017, 19, 191.	0.8	4
62	Angiotensin receptor signaling and prostate tumor growth in mice. Journal of Experimental Therapeutics and Oncology, 2017, 11, 107-115.	0.5	4
63	Adverse pathology and undetectable ultrasensitive prostateâ€specific antigen after radical prostatectomy: is adjuvant radiation warranted?. BJU International, 2016, 117, 897-903.	1.3	7
64	Effect of positive endâ€expiratory pressure on blood loss during retropubic and robotâ€assisted laparoscopic radical prostatectomy. International Journal of Urology, 2016, 23, 674-678.	0.5	4
65	Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 547-554.	1.1	15
66	Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. European Urology, 2016, 69, 885-891.	0.9	26
67	Race does not predict the development of metastases in men with nonmetastatic castrationâ€resistant prostate cancer. Cancer, 2016, 122, 3848-3855.	2.0	8
68	Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology, 2016, 96, 171-176.	0.5	55
69	Positive surgical margins in radical prostatectomy patients do not predict longâ€term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (<scp>SEARCH</scp>) cohort. BJU International, 2016, 117, 244-248.	1.3	20
70	Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer—Results from the SEARCH database. Cancer Epidemiology, 2015, 39, 1066-1070.	0.8	0
71	Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2015, 22, 658-662.	0.5	10
72	Is PSA related to serum cholesterol and does the relationship differ between black and white men?. Prostate, 2015, 75, 1877-1885.	1.2	12

#	Article	IF	CITATIONS
73	Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study. Journal of Urology, 2015, 194, 52-57.	0.2	3
74	The Association of Exercise with Both Erectile and Sexual Function in Black and White Men. Journal of Sexual Medicine, 2015, 12, 1202-1210.	0.3	20
75	Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study. Clinical Cancer Research, 2015, 21, 756-762.	3.2	91
76	Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database. Journal of Urology, 2015, 193, 1232-1238.	0.2	11
77	Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study. Clinical Cancer Research, 2014, 20, 5331-5338.	3.2	26
78	Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2936-2942.	1.1	84
79	Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2349-2356.	1.1	111
80	Alcohol Intake Increases High-grade Prostate Cancer Risk Among Men Taking Dutasteride in the REDUCE Trial. European Urology, 2014, 66, 1133-1138.	0.9	22
81	Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy. Prostate Cancer and Prostatic Diseases, 0, , .	2.0	1
82	Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urology Practice, 0, , .	0.2	O